Lascufloxacin

Lascufloxacin
Clinical data
Trade names	Lasvic
Other names	KRP-AM1977
Identifiers
	IUPAC name 7-[(3S,4S)-3-[(Cyclopropylamino)methyl]-4-fluoropyrrolidin-1-yl]-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxoquinoline-3-carboxylic acid;
CAS Number	848416-07-9 ;
PubChem CID	71528768 ;
IUPHAR/BPS	10823 ;
ChemSpider	34985131 ;
UNII	55MOB566V7 ;
KEGG	D10772 ;
CompTox Dashboard (EPA)	DTXSID001336967 ;
Chemical and physical data
Formula	C21H24F3N3O4
Molar mass	439.435 g·mol−1
3D model (JSmol)	Interactive image ;
	SMILES COC1=C2C(=CC(=C1N3C[C@@H]([C@@H](C3)F)CNC4CC4)F)C(=O)C(=CN2CCF)C(=O)O;

Last updated August 20, 2025

Lascufloxacin (trade name Lasvic) is an fluoroquinolone antibiotic drug for the treatment of bacterial infections. It has been approved since 2019 in Japan^[1] to treat community-acquired pneumonia, otorhinolaryngological infections, and respiratory tract infections.^[2]

It has activity against various Gram-positive bacteria including Streptococcus pneumoniae ^[3] and Streptococcus anginosus .^[4]

References

↑ "Kyorin Pharmaceutical Receives Marketing Approval for Oral Quinolone Antibacterial Agent Lasvic Tablets 75 mg" (PDF) (Press release). Kyorin Pharmaceutical Co. September 20, 2019. Retrieved July 3, 2021.
↑ "Lascufloxacin - Kyorin Pharmaceutical". Adis Insight. Retrieved July 3, 2021.
↑ Murata M, Kosai K, Yamauchi S, Sasaki D, Kaku N, Uno N, Morinaga Y, Hasegawa H, Miyazaki T, Izumikawa K, Mukae H, Yanagihara K (April 2018). "In Vitro Activity of Lascufloxacin against Streptococcus pneumoniae with Mutations in the Quinolone Resistance-Determining Regions". Antimicrob Agents Chemother. 62 (4) e01971-17. doi:10.1128/AAC.01971-17. PMC 5913943 . PMID 29439959.
↑ Yamagishi Y, Matsukawa Y, Suematsu H, Mikamo H (December 2018). "In vitro activity of lascufloxacin, a novel fluoroquinolone antibacterial agent, against various clinical isolates of anaerobes and Streptococcus anginosus group". Anaerobe. 54: 61–64. doi:10.1016/j.anaerobe.2018.08.002. PMID 30114441. S2CID 52015090.

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[1] "Kyorin Pharmaceutical Receives Marketing Approval for Oral Quinolone Antibacterial Agent Lasvic Tablets 75 mg" (PDF) (Press release). Kyorin Pharmaceutical Co. September 20, 2019. Retrieved July 3, 2021.

[2] "Lascufloxacin - Kyorin Pharmaceutical". Adis Insight. Retrieved July 3, 2021.

[3] Murata M, Kosai K, Yamauchi S, Sasaki D, Kaku N, Uno N, Morinaga Y, Hasegawa H, Miyazaki T, Izumikawa K, Mukae H, Yanagihara K (April 2018). "In Vitro Activity of Lascufloxacin against Streptococcus pneumoniae with Mutations in the Quinolone Resistance-Determining Regions". Antimicrob Agents Chemother. 62 (4) e01971-17. doi:10.1128/AAC.01971-17. PMC 5913943 . PMID 29439959.

[4] Yamagishi Y, Matsukawa Y, Suematsu H, Mikamo H (December 2018). "In vitro activity of lascufloxacin, a novel fluoroquinolone antibacterial agent, against various clinical isolates of anaerobes and Streptococcus anginosus group". Anaerobe. 54: 61–64. doi:10.1016/j.anaerobe.2018.08.002. PMID 30114441. S2CID 52015090.

[1]

[2]

[3]

[4]